Searched for
PHARMACEUTICAL PATENTS
The 30% smallcap tilt: How Abakkus Flexi Cap Fund is positioning for the next rallyAbakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- Piyush Goyal meets Ernst & Young CEO, discusses India's role in global supply chainsUnion Minister Piyush Goyal said he held a meeting with Janet Truncale, Global Chair and CEO of EY, to discuss India's growing role in glob...
- India's biggest trade bet comes with six red flagsIndia may be adding more trade partners, but its latest FTA report card comes with several red marks. A new study by the Global Trade Resea...
- Quote of the day by Tom Gayner: "Equities are congealed intellectual capital, and that is what I want"Investor Tom Gayner views stocks as ownership in businesses built on human ingenuity. He emphasizes that a company's value stems from its i...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- India needs to raise R&D spending to 2 pc of GDP by 2035 to boost manufacturing: ReportIndia's manufacturing growth is hampered by low R&D spending, currently at 0.6% of GDP, a report highlights. To boost its manufacturing sha...
- AbbVie loses patent plea for Hep C drugThe Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to aff...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Hospitals warn Central Government Health Scheme reimbursement cap may hurt cancer treatmentA major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement c...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- In 1856, William Henry Perkin Failed a Chemistry Experiment and Found a Purple Residue Instead: Leading to the Establishment of the First Synthetic Dye IndustryA failed experiment in 1856 led to a remarkable discovery. William Perkin found a substance that stained fabrics a vibrant purple. This led...
- US raises concerns at India’s duties on IP-intensive goods, source code, AI working paperThe US has voiced concerns over India's high customs duties on IP-intensive products and its proposed mandatory blanket license for AI deve...
- Hindustan Labs, RK Steel get Sebi nod to launch IPOsHindustan Laboratories has received Sebi's observations, a crucial step towards its IPO, which includes a fresh issue and an offer for sale...
Load More
